A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-11. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
=== Recent === Flat-screen display technology began in the 2000s, replacing the cathode-ray tube displays of the previous century. In the years that followed, technology evolved and displays became increasingly thinner, higher in resolution and larger. As a result, the required composite structures become increasingly complex, and the manufacturing methods became more demanding. Edwards Vacuum is involved in flat-screen display production with its turbomolecular pumps, which enable the high levels of vacuum required for the production process and coating of these displays. Abatement installations remove global warming, toxic, pyrophoric, and corrosive gases in a safe, regulatory way. Vacuum coating is used in other industries, including solar cell photovoltaics. They are produced with processes such as crystalline silicon, CdTe, CIGS, or Silicon Thin Film Technology, all of which require vacuum. Lithium-ion batteries are a rapidly growing market, that also requires large amounts of vacuum in various stages of their production. Edwards CTI-Cryogenics and Edwards Polycold cryopumps and cryochillers play their role in cryogenic fields: MRI machines that uses liquid helium and require cryogenic cooling, storage of large quantities of food, freezing of blood and tissues samples, and semiconductors, as their technology and structures become more complex.
Satellite phone (satphone) – a portable wireless telephone similar to a cell phone, connected to the telephone network through a radio link to an orbiting communications satellite instead of through cell towers. They are more expensive than cell phones; but their advantage is that, unlike a cell phone which is limited to areas covered by cell towers, satphones can be used over most or all of the geographical area of the Earth. In order for the phone to communicate with a satellite using a small omnidirectional antenna, first-generation systems use satellites in low Earth orbit, about 400–700 miles (640–1,100 km) above the surface. With an orbital period of about 100 minutes, a satellite can only be in view of a phone for about 4 – 15 minutes, so the call is "handed off" to another satellite when one passes beyond the local horizon. Therefore, large numbers of satellites, about 40 to 70, are required to ensure that at least one satellite is in view continuously from each point on Earth. Other satphone systems use satellites in geostationary orbit in which only a few satellites are needed, but these cannot be used at high latitudes because of terrestrial interference. Cordless phone – a landline telephone in which the handset is portable and communicates with the rest of the phone by a short-range full duplex radio link, instead of being attached by a cord. Both the handset and the base station have low-power radio transceivers that handle the short-range bidirectional radio link. As of 2022, cordless phones in most nations use the DECT transmission standard.
The following is a timeline of the second presidency of Donald Trump during the fourth and last quarter of 2025, from October 1, 2025, to December 31, 2025. To navigate between quarters, see timeline of the Donald Trump presidencies.
Sources: en.wikipedia.org
==== Withdrawn ==== Josh Cortez, former advisor to U.S. representative Monica De La Cruz (ran in the 35th district) Mayra Flores, former U.S. representative from the 34th district (2022–2023) (ran in the 34th district) Jay Furman, physician and nominee for this district in 2024 (ran in the 35th district)
The chest x-ray is distinctive with features that appear similar to an extensive pneumonia, with both lungs showing widespread white patches. The white patches may seem to migrate from one area of the lung to another as the disease persists or progresses. Computed tomography (CT) may be used to confirm the diagnosis. Often the findings are typical enough to allow the doctor to make a diagnosis without ordering additional tests. To confirm the diagnosis, a doctor may perform a lung biopsy using a bronchoscope. Many times, a larger specimen is needed and must be removed surgically. Plain chest radiography shows normal lung volumes, with characteristic patchy unilateral or bilateral consolidation. Small nodular opacities occur in up to 50% of patients and large nodules in 15%. On high resolution computed tomography, airspace consolidation with air bronchograms is present in more than 90% of patients, often with a lower zone predominance. A subpleural or peribronchiolar distribution is noted in up to 50% of patients. Ground glass appearance or hazy opacities associated with the consolidation are detected in most patients. Histologically, cryptogenic organizing pneumonia is characterized by the presence of polypoid plugs of loose organizing connective tissue (Masson bodies) within alveolar ducts, alveoli, and bronchioles.
=== Tandem in space MS/MS modes === When tandem MS is performed with an in space design, the instrument must operate in one of a variety of modes. There are a number of different tandem MS/MS experimental setups and each mode has its own applications and provides different information. Tandem MS in space uses the coupling of two instrument components which measure the same mass spectrum range but with a controlled fractionation between them in space, while tandem MS in time involves the use of an ion trap. There are four main scan experiments possible using MS/MS: precursor ion scan, product ion scan, neutral loss scan, and selected reaction monitoring. For a precursor ion scan, the product ion is selected in the second mass analyzer, and the precursor masses are scanned in the first mass analyzer. Note that precursor ion is synonymous with parent ion and product ion with daughter ion; however the use of these anthropomorphic terms is discouraged. In a product ion scan, a precursor ion is selected in the first stage, allowed to fragment and then all resultant masses are scanned in the second mass analyzer and detected in the detector that is positioned after the second mass analyzer. This experiment is commonly performed to identify transitions used for quantification by tandem MS. In a neutral loss scan, the first mass analyzer scans all the masses. The second mass analyzer also scans, but at a set offset from the first mass analyzer. This offset corresponds to a neutral loss that is commonly observed for the class of compounds.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.